Hartland,

This article is a little outdated, but as of its publication in May 2014 there were only three classes of HDL-raising drugs in Phase II or later trials: RVX-208 (apabetalone), CETP inhibitors (anacetrapib, evacetrapib, Dezima's TA-8995), and HDL-infusion therapies. Of these three classes, only RVX-208 and CETP inhibitors are orally available. Of these three classes, only CETP inhibitors and RVX-208 (once BETonMACE starts) will have advanced to Phase III trials. CETP inhibitors have baggage (two other CETP inhibitors have failed). RVX-208 has baggage (still lurking in the shadows of ASSURE). However, the spotlight will soon be shining on RVX-208. It is hard to hide an HDL-raising therapy in Phase III trials from media attention. Once this spotlight shines upon BETonMACE, the shadows of ASSURE/SUSTAIN will no longer be dwelled upon. We will look back upon the post-hoc ASSURE/SUSTAIN analysis as a positive, pivotal point in the clinical development of RVX-208 (apabetalone) and as BETonMACE proceeds we will be talking about the "bookends" getting closer and closer together like we did for ASSURE. However, this time around we have a more refined mechanism of action, a more refined patient population, more refined endpoints and a better powered study. Yes, I agree that right now Resverlogix/RVX-208/Apabetalone is not widely known. But going into a Phase III, for an HDL-raising, MACE/CVD reducing therapy, overseen by a STELLAR international steering committee, enrolling patients from at least 2 (hopefully 3) continents, knowing what we know for the RRR of the post-hoc ASSURE/SUSTAIN........this won't be kept under wraps for long and the cat will be out of the bag soon enough. Fall is approaching.